NasdaqGS:ANNX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune and neurodegenerative diseases. More Details


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has Annexon's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ANNX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: Insufficient data to determine ANNX's volatility change over the past year.


Market Performance


7 Day Return

23.0%

ANNX

4.4%

US Biotechs

0.6%

US Market


1 Year Return

n/a

ANNX

36.0%

US Biotechs

21.0%

US Market

Return vs Industry: Insufficient data to determine how ANNX performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how ANNX performed against the US Market.


Shareholder returns

ANNXIndustryMarket
7 Day23.0%4.4%0.6%
30 Day6.2%5.6%4.2%
90 Day-9.5%19.2%12.4%
1 Yearn/a38.2%36.0%23.7%21.0%
3 Yearn/a31.5%24.6%47.4%37.6%
5 Yearn/a48.8%37.4%131.6%105.9%

Long-Term Price Volatility Vs. Market

How volatile is Annexon's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Annexon undervalued compared to its fair value and its price relative to the market?

2.87x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ANNX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ANNX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ANNX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ANNX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ANNX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ANNX is good value based on its PB Ratio (2.9x) compared to the US Biotechs industry average (4.3x).


Next Steps

Future Growth

How is Annexon forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-15.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ANNX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ANNX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ANNX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if ANNX's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if ANNX's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ANNX is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Annexon performed over the past 5 years?

-66.4%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: ANNX is currently unprofitable.

Growing Profit Margin: ANNX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if ANNX's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare ANNX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ANNX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).


Return on Equity

High ROE: ANNX has a negative Return on Equity (-13.45%), as it is currently unprofitable.


Next Steps

Financial Health

How is Annexon's financial position?


Financial Position Analysis

Short Term Liabilities: ANNX's short term assets ($373.6M) exceed its short term liabilities ($9.0M).

Long Term Liabilities: ANNX's short term assets ($373.6M) exceed its long term liabilities ($1.1M).


Debt to Equity History and Analysis

Debt Level: ANNX is debt free.

Reducing Debt: ANNX had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ANNX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: ANNX has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 33.5% each year


Next Steps

Dividend

What is Annexon current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ANNX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ANNX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ANNX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ANNX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ANNX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.6yrs

Average management tenure


CEO

Doug Love (53 yo)

6.08yrs

Tenure

US$3,388,240

Compensation

Mr. Douglas Love, Esq., J.D, also known as Doug, has been the President, Director and Chief Executive Officer of Annexon Inc. since December 2014. He has extensive business and legal leadership experience ...


CEO Compensation Analysis

Compensation vs Market: Doug's total compensation ($USD3.39M) is above average for companies of similar size in the US market ($USD2.38M).

Compensation vs Earnings: Doug's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Douglas Love
CEO, President & Director6.08yrsUS$3.39mno data
Jennifer Lew
Executive VP & CFO1.58yrsUS$1.46m0.0052%
$ 54.9k
Sanjay Keswani
Executive VP & Chief Medical Officer1.58yrsUS$1.79m0%
$ 0
Arnon Rosenthal
no datano datano data
Ted Yednock
Executive VP & Chief Scientific Officer7.17yrsno datano data
Michael Overdorf
Executive VP & Chief Business Officer0.50yrno datano data
Mirella Del Toro
Secretaryno datano datano data

1.6yrs

Average Tenure

51.5yo

Average Age

Experienced Management: ANNX's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Douglas Love
CEO, President & Director6.08yrsUS$3.39mno data
Muneer Satter
Independent Director6.08yrsno data2.12%
$ 22.2m
William Young
Independent Chairman3.83yrsUS$115.11k0%
$ 0
Thomas Wiggans
Independent Director3.92yrsUS$35.97k0%
$ 0
Dennis Henner
Member of Scientific Advisory Boardno datano datano data
Edward Scolnick
Member of Scientific Advisory Boardno datano datano data
Thomas Maniatis
Member of Scientific Advisory Boardno datano datano data
Carol Gallagher
Independent Director2.25yrsno datano data
David Holtzman
Member of Scientific Advisory Boardno datano datano data
Stephen Hauser
Member of Scientific Advisory Boardno datano datano data
Ricky Sun
Independent Director2.08yrsno datano data
P. Willison
Member of Scientific Advisory Boardno datano datano data

3.9yrs

Average Tenure

68yo

Average Age

Experienced Board: ANNX's board of directors are considered experienced (3.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: ANNX only recently listed within the past 12 months.


Top Shareholders

Company Information

Annexon, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Annexon, Inc.
  • Ticker: ANNX
  • Exchange: NasdaqGS
  • Founded: 2011
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.047b
  • Shares outstanding: 38.16m
  • Website: https://www.annexonbio.com

Number of Employees


Location

  • Annexon, Inc.
  • 180 Kimball Way
  • 2nd Floor
  • South San Francisco
  • California
  • 94080
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ANNXNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJul 2020

Biography

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune and neurodegenerative diseases. It focuses on the treatment of body, brain, and eye disorders. ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/16 00:26
End of Day Share Price2021/01/15 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.